Matthew Gregory Cohen
Director · ARROWHEAD PHARMACEUTICALS, INC.
Individual
- 2026
- Jun 18, 2026
- 1
Filings (90d)
Other insiders active in the same stocks
Insiders who reported open-market trades in the last 12 months at the companies Matthew Gregory Cohen files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Christopher Richard Anzalone - $12.35M in ARWR purchases and sales in the last 12 months
- James C. Hamilton - $1.39M in ARWR purchases and sales in the last 12 months
- Michael S. Perry - $1.01M in ARWR purchases and sales in the last 12 months
- Daniel Joseph Apel - $934K in ARWR purchases and sales in the last 12 months
- Mauro Ferrari - $493K in ARWR purchases and sales in the last 12 months
- Hongbo Lu - $228K in ARWR purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Frequently asked questions
Who is Matthew Gregory Cohen?
Matthew Gregory Cohen is a corporate insider, tracked as Director of ARROWHEAD PHARMACEUTICALS, INC. (ARWR). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
When did Matthew Gregory Cohen last file a Form 4?
The only primary Form 4 on record is dated 18 June 2026.
